In an industry first, all ongoing studies
migrated to Vault EDC from legacy EDC
BARCELONA, Spain, Jan. 17, 2024 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today announced a top 20 biopharma and Veeva Services
migrated 25 ongoing clinical studies to Veeva Vault EDC from a
legacy electronic data capture (EDC) application. This successful
migration of an entire core study portfolio – including a large
study with more than 500 research sites and 7,000 patients – is an
important industry first. With migrations complete, the customer
plans to use Vault EDC for all current and future trials
globally.
Life sciences companies have historically avoided migrating
studies due to technical challenges, complex data models, and risk
concerns. Vault EDC's proprietary migration capability enables
Veeva Services to migrate ongoing studies securely with minimal
disruption. With this top 20 biopharma, Vault EDC was used to
migrate more than 55 million data points and five million forms
safely and efficiently.
"Locked down legacy systems and perceived risks have made the
topic of migrating studies a non-starter," said Drew Garty, chief technology officer, Veeva
Vault CDMS. "Biopharma companies can now reliably migrate ongoing
studies from their legacy applications to Veeva Vault EDC with a
repeatable approach that can reduce fees, drive standardization,
and provide a better site experience."
Vault EDC's migration capability enables customers to
decommission legacy EDC systems while advancing clinical data
management. To learn more about Vault EDC, visit
veeva.com/eu/VaultEDC.
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com/eu.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and services
and the expected results or benefits from use of our products and
services. These statements are based on our current expectations.
Actual results could differ materially from those provided in this
release and we have no obligation to update such statements. There
are numerous risks that have the potential to negatively impact our
results, including the risks and uncertainties disclosed in our
filing on Form 10-Q for the period ended October 31, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 38 and 39), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
|
|
Jeremy Whittaker
|
Deivis
Mercado
|
Veeva
Systems
|
Veeva
Systems
|
+49-695-095-5486
|
925-226-8821
|
jeremy.whittaker@veeva.com
|
deivis.mercado@veeva.com
|
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/veeva-completes-study-migrations-to-veeva-vault-edc-for-top-biopharma-302036648.html